Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the...
Ziopharm Oncology (ZIOP -6.2%) drops following a blog report in Forbes.com that accuses the company of failing to disclose an FDA warning letter. The blogger, an investor short on the stock, says the FDA admonished a clinical investigator hired by ZIOP for multiple violations in a mid-stage study of Palifosfamide, its investigational cancer drug. The study in question has since advanced into a late-stage trial with results expected before 2013.
From other sites
at Nasdaq.com (Wed, 12:09PM)
at CNBC.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at MarketWatch.com (Jan 14, 2015)
at Nasdaq.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs